Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-330 and D086 in Hypertensive Patients With Dyslipidemia
NCT03583905Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan + amlodipine and D086 in hypertension (HTN) and dyslipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Change rate from baseline in LDL-C at 8 weeks and Change from baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Apr 2018; status: completed.
02
Drugs
candesartan + amlodipineD086
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03583905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583905.